Although the expression of VISTA on CD4+ T cells has been implicated in tumor progression in a recent study, it should be cautiously assumed based on the small patient numbers that the expression of VISTA on CD4+ T cells may be a novel clinical prognostic parameter for NSCLC. The gene discussed is VSIR; the disease is neoplasm.